Scientists Find New Way to Target HIV Hiding in Body

For decades, scientists believed HIV hid silently in infected cells during treatment, but a new discovery shows the virus is far more active than anyone realized.

Researchers at Gladstone Institutes developed a powerful new tool called HIV-seq that can finally spot the infected cells that standard tests miss. Using this method, they found that some HIV reservoir cells keep producing viral fragments even when antiretroviral therapy stops the virus from fully replicating.

This hidden activity explains two major mysteries that have puzzled doctors for years. First, it reveals why HIV bounces back so quickly when people stop treatment. Second, it shows why patients on therapy still experience chronic inflammation that can damage organs and increase heart disease risk over time.

"The notion that the entirety of the HIV reservoir is latent is actually a misleading description, because some reservoir cells can still be quite active," said Dr. Nadia Roan, senior investigator at Gladstone Institutes. Her team's work gives scientists their clearest view yet of how HIV survives in the body.

The breakthrough came from fixing a gap in existing technology. Standard single-cell RNA sequencing often detected only one or two infected cells per patient, far too few to study meaningfully. HIV-seq uses targeted primers that recognize multiple regions of the HIV genome, capturing viral fragments that older tools completely missed.

The improvement was dramatic. In patients on therapy, the new method detected 25 infected cells from just three individuals, compared to the one or two found before.

Why This Inspires

What makes this discovery truly hopeful is what it reveals about how HIV adapts. In untreated patients, the virus thrives in aggressive, inflammatory cells that spread infection quickly. But under treatment, HIV shifts strategy completely.

The infected cells that survive therapy look entirely different. They're quieter, less inflammatory, and built for long-term survival. They express specific genes that help them avoid cell death and persist for years.

Here's the exciting part: some of those survival genes are already targets of drugs being tested in clinical trials right now. "This is noteworthy because there is an ongoing clinical trial testing a drug targeting a pathway that HIV may use to preferentially promote survival of its host cell," said Dr. Steven Yukl, a physician-scientist at the San Francisco VA Medical Center.

For people living with HIV, antiretroviral therapy has already transformed the disease from a death sentence to a manageable condition. This research takes the next step by showing scientists exactly where to aim future treatments.

The study gives researchers a roadmap for developing therapies that could eliminate these persistent cells entirely. Instead of just suppressing the virus, future treatments might actually cure it.

After 40 years of fighting HIV, scientists finally have the tools to see what they're up against and the knowledge to design better weapons.